Nearly 1 million Americans live with multiple sclerosis (MS), an autoimmune disorder of the central nervous system that typically begins between ages 20 and 50. MS was once considered an inevitably progressive and disabling disease; today, with more than 20 disease-modifying therapies and improved early diagnosis, many patients maintain near-normal function for decades. The condition affects women roughly three times more often than men, and rates are higher in higher latitudes — a clue to its complex origins.
This guide covers MS types, symptoms, diagnosis, and current treatment landscape. For more on related autoimmune and neurological conditions, see our medical conditions resource hub.
What MS Is
MS is an immune-mediated condition in which the body’s own T cells and B cells attack myelin — the insulating sheath surrounding nerve fibers in the brain, spinal cord, and optic nerves. Inflammation produces lesions visible on MRI. Over time, damage extends to the underlying axons, producing the progressive disability characteristic of advanced disease.
According to the National Institute of Neurological Disorders and Stroke, MS prevalence in the US is approximately 363 per 100,000, with substantial geographic variation. Onset typically occurs between ages 20-50, though pediatric MS exists.
The Four Types of MS
Relapsing-remitting MS (RRMS) is the most common form at diagnosis (about 85% of cases). It involves discrete relapses with new neurologic symptoms followed by complete or partial recovery. Periods between relapses show no disease progression.
Secondary progressive MS (SPMS) develops in many RRMS patients eventually, with gradual worsening between (or in absence of) relapses. The natural history showed roughly half of RRMS converted to SPMS within 10-15 years before modern treatments; current therapies have substantially modified this trajectory.
Primary progressive MS (PPMS) affects 10-15% of patients and involves gradual worsening from onset without distinct relapses. Clinically isolated syndrome (CIS) describes the first MS-like episode; some progress to clinically definite MS while others have a single event.
Common Symptoms
Symptoms depend on lesion location. Common presentations include optic neuritis (vision loss with painful eye movement), sensory symptoms (numbness, tingling, electric shock with neck flexion known as Lhermitte’s sign), motor weakness, balance and coordination problems, and bladder dysfunction.
Per Mayo Clinic, fatigue is the most common and often most disabling symptom, affecting roughly 80% of patients. Cognitive changes — particularly slowed processing speed and memory — affect roughly half of patients at some point. Spasticity, neuropathic pain, sexual dysfunction, and depression are also common.
Triggers of Relapse and Progression
Heat sensitivity (Uhthoff’s phenomenon) produces transient worsening of symptoms with elevated body temperature — hot weather, hot showers, fever, or exercise. These are not true relapses but reflect impaired conduction in already-damaged nerves. Stress and infections can trigger genuine relapses in some patients.
Pregnancy reduces relapse risk during the second and third trimesters but increases risk in the postpartum period. Vitamin D deficiency, low sun exposure, smoking, and obesity all show association with worse MS course in observational studies.
Causes and Risk Factors
MS results from interaction between genetic susceptibility and environmental triggers. Genetics contribute moderately: having a first-degree relative with MS raises risk to roughly 2-4% (versus 0.3% in the general population). The HLA-DRB1*1501 variant is the strongest single genetic risk factor.
Environmental factors include Epstein-Barr virus infection (EBV) — a 2022 Harvard study of 10 million US military personnel showed EBV infection precedes MS in essentially all cases, raising risk 32-fold. Vitamin D deficiency, smoking, low sun exposure, childhood obesity, and certain occupational exposures also contribute. Geographic gradient — higher prevalence farther from the equator — has been recognized for decades.
Diagnosis
MS is diagnosed using the McDonald criteria, which require evidence of CNS damage in time and space. MRI of the brain and spinal cord is the cornerstone, showing characteristic white matter lesions in periventricular, juxtacortical, infratentorial, and spinal cord locations. Active lesions enhance with gadolinium contrast.
Spinal fluid analysis can support diagnosis (oligoclonal bands present in 90%+ of MS patients). Visual evoked potentials may reveal subclinical optic nerve involvement. Differential diagnosis includes neuromyelitis optica spectrum disorder (NMOSD), MOG antibody-associated disease, vasculitis, B12 deficiency, Lyme disease, and other inflammatory or infectious conditions.
Disease-Modifying Therapies
The treatment landscape has transformed since the first DMT (interferon beta-1b) approved in 1993. More than 20 DMTs are now available, generally categorized by efficacy and mechanism. Per Cleveland Clinic, current practice often favors high-efficacy therapy early to prevent disability accumulation.
Injectable agents include interferon betas and glatiramer acetate — modest efficacy, established safety. Oral DMTs include dimethyl fumarate, fingolimod, teriflunomide, and ozanimod — moderate efficacy with varied side effect profiles. Infusion therapies include natalizumab, ocrelizumab, ofatumumab, alemtuzumab, and the newer ublituximab — generally highest efficacy with greater monitoring requirements.
Ocrelizumab (Ocrevus) was the first DMT FDA-approved for primary progressive MS, modestly slowing progression in selected patients. Costs are substantial: most DMTs run $70,000-$100,000+ per year list price, though insurance coverage and patient assistance programs typically reduce out-of-pocket significantly.
Acute Relapse Treatment
Significant relapses are typically treated with high-dose corticosteroids — methylprednisolone 1,000 mg IV daily for 3-5 days, sometimes followed by oral taper. Steroids speed recovery from acute symptoms but do not affect long-term outcome. For severe steroid-refractory relapses, plasma exchange (plasmapheresis) is sometimes used.
Symptom Management
Beyond DMTs, symptomatic treatment substantially affects quality of life. Fatigue may respond to amantadine, modafinil, or methylphenidate. Spasticity is treated with baclofen, tizanidine, or onabotulinumtoxinA injections. Bladder symptoms respond to anticholinergics, beta-3 agonists, or onabotulinumtoxinA. Neuropathic pain often responds to gabapentin, pregabalin, or duloxetine. Depression is treated as in non-MS populations.
Physical therapy, occupational therapy, and exercise programs play essential roles. Dalfampridine (Ampyra) improves walking speed in roughly one-third of patients. Cooling strategies — vests, scarves, swimming — help heat-sensitive patients.
When to See a Doctor
Sudden vision changes, numbness or weakness, balance problems, or other neurologic symptoms — particularly lasting more than 24 hours — warrant prompt evaluation. Early diagnosis matters because early DMT initiation produces better long-term outcomes. Most diagnosis and ongoing management occurs through neurology, often subspecialized MS clinics.
MS care can be expensive but is largely covered by insurance. Specialty pharmacy programs, manufacturer copay assistance, and the National MS Society’s MS Navigator service help with access. Telehealth has expanded MS care access, though some procedures (infusions, MRI) remain in-person.
Frequently Asked Questions
Is multiple sclerosis fatal?
MS is rarely directly fatal, and life expectancy is reduced by only a few years compared to the general population. Severe complications (immobility, swallowing difficulties, infections) can shorten life in advanced disease. Most MS-related deaths involve complications rather than the disease itself.
Can MS be cured?
There is no cure for MS, but disease-modifying therapies substantially alter the disease course. Some patients on high-efficacy DMTs achieve “no evidence of disease activity” (NEDA) — no relapses, no MRI activity, no progression — for many years. Stem cell transplantation produces durable remission in selected severe cases.
Is MS hereditary?
Genetics contribute modestly. Having a first-degree relative with MS raises lifetime risk from 0.3% to 2-4%. Identical twins of MS patients have roughly 25% concordance. MS is not considered a single-gene inherited disorder.
Should people with MS exercise?
Yes. Regular exercise is now recommended as part of MS care. It improves fatigue, mood, mobility, and overall function, with no evidence of triggering relapses. Heat-sensitive patients may benefit from cooling strategies and aquatic exercise.
The Bottom Line
Multiple sclerosis has been transformed by modern disease-modifying therapies, with many patients now maintaining stable function for decades. Early diagnosis and treatment matter — current evidence supports earlier and often higher-efficacy DMT use. Symptomatic management, exercise, and rehabilitation also substantially improve quality of life. If neurologic symptoms suggesting MS are arising, prompt evaluation with neurology can shape the long-term course considerably.